


**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1.-6. (Cancelled)

7. (Currently Amended) ~~The A compound of Claim 4 wherein~~ of formula (Ia):



wherein:

the A, C or D ring is independently fully saturated;

C1, C4, C11, C12, C15 and C16 are each independently substituted with two hydrogens;

C9 and C14 are each independently substituted with hydrogen;

R<sup>1</sup> is -OR<sup>7</sup>;

R<sup>2</sup> is -R<sup>8</sup>-OR<sup>7</sup>;

R<sup>3</sup> is -R<sup>10</sup>-N(R<sup>7</sup>)<sub>2</sub>;

~~R<sup>4a</sup> and R<sup>4b</sup> are each independently selected from hydrogen, alkenyl or alkynyl;~~

~~or R<sup>4a</sup> is hydrogen, alkenyl or alkynyl and R<sup>4b</sup> is a direct bond to the carbon at C16;~~

~~or R<sup>4a</sup> and R<sup>4b</sup> together form alkylidene or haloalkylidene;~~

~~R<sup>5</sup> is alkyl or R<sup>5</sup> is a direct bond to the carbon at C14;~~

R<sup>6</sup> is hydrogen, -R<sup>8</sup>-OR<sup>7</sup> or -R<sup>8</sup>-N(R<sup>7</sup>)<sub>2</sub>;

each R<sup>7</sup> is independently selected from the group consisting of hydrogen, -R<sup>10</sup>-OR<sup>9</sup>, -R<sup>10</sup>-N(R<sup>9</sup>)<sub>2</sub>, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl;

each R<sup>8</sup> is independently selected from the group consisting of a direct bond, a straight or branched alkylene chain, and a straight or branched alkenylene chain;

each R<sup>9</sup> is independently selected from the group consisting of hydrogen, alkyl, aryl and aralkyl; and

each R<sup>10</sup> is independently selected from the group consisting of a straight or branched alkylene and a straight or branched alkenylene chain,

as a single stereoisomer, a mixture of stereoisomers, or as a racemic mixture of stereoisomers;

or a pharmaceutically acceptable salt, solvate or prodrug thereof.

8. (Currently Amended) The compound of Claim 7 selected from the group consisting of the following:

5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -hydroxymethylcyclohexyl)-4 $\alpha$ -aminomethyl-7a $\beta$ -methyl-1-ethylideneoctahydroindene, ammonium chloride salt;

5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -hydroxymethylcyclohexyl)-4 $\alpha$ -aminomethyl-7a $\beta$ -methyl-1-methyleneoctahydroindene, ammonium acetate salt;

5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -hydroxymethylcyclohexyl)-4 $\alpha$ -aminomethyl-7a $\beta$ -methyl-1-methyleneoctahydroindene, ammonium chloride salt;

5-(1 $\beta$ -methyl-2 $\beta$ ,4 $\beta$ -dihydroxycyclohexyl)-4 $\alpha$ -(2-aminoethyl)-7a $\beta$ -methyl-1-methyleneoctahydroindene;

5-(1 $\beta$ -methyl-2 $\beta$ ,4 $\beta$ -dihydroxycyclohexyl)-4 $\alpha$ -(2-aminoethyl)-7a $\beta$ -methyl-1-methyleneoctahydroindene, ammonium acetate salt;

5-(1 $\beta$ -methyl-2 $\beta$ ,4 $\beta$ -dihydroxycyclohexyl)-4 $\alpha$ -aminomethyl-7a $\beta$ -methyl-1-methyleneoctahydroindene;

5-(1 $\beta$ -methyl-2 $\beta$ ,4 $\beta$ -dihydroxycyclohexyl)-4 $\alpha$ -aminomethyl-7a $\beta$ -methyl-1-methyleneoctahydroindene, ammonium acetate salt;

5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -hydroxymethylcyclohexyl)-4 $\alpha$ -aminomethyl-7a $\beta$ -methyl-1-difluoromethyleneoctahydroindene;

5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -hydroxymethylcyclohexyl)-4 $\alpha$ -aminomethyl-7a $\beta$ -methyl-1-difluoromethyleneoctahydroindene, ammonium chloride salt;

5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -hydroxymethylcyclohexyl)-4 $\alpha$ -aminomethyl-7a $\beta$ -methyl-1-dichloromethyleneoctahydroindene, ammonium chloride salt;

~~5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -hydroxymethylcyclohexyl)-4 $\alpha$ -aminomethyl-7a $\beta$ -methyl-1 $\beta$ -(propen-2-yl)octahydroindene;~~

5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -hydroxymethylcyclohexyl)-4 $\alpha$ -aminomethyl-7 $\alpha\beta$ -methyl-1 $\beta$ -(propen-2-yl)octahydroindene, ammonium acetate salt;

5-(1 $\beta$ -methyl-4 $\alpha$ ,5 $\alpha$ -dihydroxy-2 $\beta$ -hydroxymethylcyclohexyl)-4 $\alpha$ -aminomethyl-7 $\alpha\beta$ -methyl-1-methylenooctahydroindene, ammonium acetate salt;

5-(1 $\beta$ -methyl-2 $\beta$ ,4 $\beta$ -dihydroxycyclohexyl)-4 $\alpha$ -(4-dimethylaminobut-2Z-en-1-yl)-7 $\alpha\beta$ -methyl-1-methylenooctahydroindene;

5-(1 $\beta$ -methyl-2 $\beta$ ,4 $\beta$ -dihydroxycyclohexyl)-4 $\alpha$ -(4-dimethylaminobut-2Z-en-1-yl)-7 $\alpha\beta$ -methyl-1-methylenooctahydroindene, ammonium acetate salt;

5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -hydroxymethylcyclohexyl)-4 $\alpha$ -(ethyl)aminomethyl-7 $\alpha\beta$ -methyl-1-methylenooctahydroindene, ammonium acetate salt;

5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -hydroxymethylcyclohexyl)-4 $\alpha$ -(benzyl)aminomethyl-7 $\alpha\beta$ -methyl-1-methylenooctahydroindene, ammonium acetate salt;

5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -hydroxymethylcyclohexyl)-4 $\alpha$ -(cyclopropylmethyl)aminomethyl-7 $\alpha\beta$ -methyl-1-methylenooctahydroindene, ammonium acetate salt;

5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -hydroxymethylcyclohexyl)-4 $\alpha$ -(dimethyl)aminomethyl-7 $\alpha\beta$ -methyl-1-methylenooctahydroindene;

5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -hydroxymethylcyclohexyl)-4 $\alpha$ -(dimethyl)aminomethyl-7 $\alpha\beta$ -methyl-1-methylenooctahydroindene, ammonium acetate salt;

5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -hydroxymethylcyclohexyl)-4 $\alpha$ -(methyl)aminomethyl-7 $\alpha\beta$ -methyl-1-methylenooctahydroindene;

5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -hydroxymethylcyclohexyl)-4 $\alpha$ -(methyl)aminomethyl-7 $\alpha\beta$ -methyl-1-methylenooctahydroindene, ammonium acetate salt;

5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -hydroxymethylcyclohexyl)-4 $\alpha$ -(2-methylpropyl)aminomethyl-7 $\alpha\beta$ -methyl-1-methylenooctahydroindene;

5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -hydroxymethylcyclohexyl)-4 $\alpha$ -(2-methylpropyl)aminomethyl-7 $\alpha\beta$ -methyl-1-methylenooctahydroindene, ammonium acetate salt;

5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -hydroxymethylcyclohexyl)-4 $\alpha$ -(1-methylpiperidin-4-yl)aminomethyl-7 $\alpha\beta$ -methyl-1-methylenooctahydroindene, ammonium diacetate salt;

5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -hydroxymethylcyclohexyl)-4 $\alpha$ -(3-nitrobenzyl)aminomethyl-7 $\alpha\beta$ -methyl-1-methylenooctahydroindene, ammonium acetate salt;

5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -hydroxymethylcyclohexyl)-4 $\alpha$ -(piperonyl)aminomethyl-7 $\alpha\beta$ -methyl-1-methylenooctahydroindene, ammonium acetate salt;

5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -hydroxymethylcyclohexyl)-4 $\alpha$ -(pyrrol-2-ylmethyl)aminomethyl-7a $\beta$ -methyl-1-methyleneoctahydroindene, ammonium acetate salt;

5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -hydroxymethylcyclohexyl)-4 $\alpha$ -(furfuryl)aminomethyl-7a $\beta$ -methyl-1-methyleneoctahydroindene, ammonium acetate salt;

5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -hydroxymethylcyclohexyl)-4 $\alpha$ -(pyridin-3-ylmethyl)aminomethyl-7a $\beta$ -methyl-1-methyleneoctahydroindene, ammonium acetate salt;

5-(1 $\beta$ -methyl-2 $\beta$ ,4 $\beta$ -dihydroxycyclohexyl)-4 $\alpha$ -(2-methylpropyl)aminomethyl-7a $\beta$ -methyl-1-methyleneoctahydroindene, ammonium acetate salt;

5-(1 $\beta$ -methyl-2 $\beta$ ,4 $\beta$ -dihydroxycyclohexyl)-4 $\alpha$ -(pyridin-3-ylmethyl)aminomethyl-7a $\beta$ -methyl-1-methyleneoctahydroindene;

5-(1 $\beta$ -methyl-2 $\beta$ ,4 $\beta$ -dihydroxycyclohexyl)-4 $\alpha$ -(2-hydroxyethyl)aminomethyl-7a $\beta$ -methyl-1-methyleneoctahydroindene, ammonium acetate salt;

5-(1 $\beta$ -methyl-2 $\beta$ ,4 $\beta$ -dihydroxycyclohexyl)-4 $\alpha$ -(furfuryl)aminomethyl-7a $\beta$ -methyl-1-methyleneoctahydroindene, ammonium acetate salt;

5-(1 $\beta$ -methyl-2 $\beta$ ,4 $\beta$ -dihydroxycyclohexyl)-4 $\alpha$ -(2-dimethylaminoethyl)aminomethyl-7a $\beta$ -methyl-1-methyleneoctahydroindene, ammonium acetate salt;

5-(1 $\beta$ -methyl-2 $\beta$ ,4 $\beta$ -dihydroxycyclohexyl)-4 $\alpha$ -(2-cyclohex-1-en-1-ylethyl)aminomethyl-7a $\beta$ -methyl-1-methyleneoctahydroindene, ammonium acetate salt;

5-(1 $\beta$ -methyl-2 $\beta$ ,4 $\beta$ -dihydroxycyclohexyl)-4 $\alpha$ -(2-morpholin-4-ylethyl)aminomethyl-7a $\beta$ -methyl-1-methyleneoctahydroindene, ammonium acetate salt;


5-(1 $\beta$ -methyl-2 $\beta$ ,4 $\beta$ -dihydroxycyclohexyl)-4 $\alpha$ -(3-methylphenyl)aminomethyl-7a $\beta$ -methyl-1-methyleneoctahydroindene;

5-(1 $\beta$ -methyl-2 $\beta$ ,4 $\beta$ -dihydroxycyclohexyl)-4 $\alpha$ -(benzyl)aminomethyl-7a $\beta$ -methyl-1-methyleneoctahydroindene; and

5-(1 $\beta$ -methyl-2 $\beta$ ,4 $\beta$ -dihydroxycyclohexyl)-4 $\alpha$ -(2-(3-methylphenyl)aminoethyl)-7a $\beta$ -methyl-1-methyleneoctahydroindene.

9.-21 (Cancelled)

22. (Currently Amended) A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of formula (Ia):



wherein:

the A, C or D ring is independently fully saturated;

C1, C4, C11, C12, C15 and C16 are each independently substituted with two hydrogens;

C9 and C14 are each independently substituted with hydrogen;

R<sup>1</sup> is -OR<sup>7</sup>;

R<sup>2</sup> is -R<sup>8</sup>-OR<sup>7</sup>;

R<sup>3</sup> is -R<sup>10</sup>-N(R<sup>7</sup>)<sub>2</sub>;

R<sup>4a</sup> and R<sup>4b</sup> together form alkylidene or haloalkylidene;

R<sup>5</sup> is alkyl;

R<sup>6</sup> is hydrogen, -R<sup>8</sup>-OR<sup>7</sup> or -R<sup>8</sup>-N(R<sup>7</sup>)<sub>2</sub>;

each R<sup>7</sup> is independently selected from the group consisting of hydrogen, -R<sup>10</sup>-OR<sup>9</sup>, -R<sup>10</sup>-N(R<sup>9</sup>)<sub>2</sub>, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl;


each R<sup>8</sup> is independently selected from the group consisting of a direct bond, a straight or branched alkylene chain, and a straight or branched alkenylene chain;

each R<sup>9</sup> is independently selected from the group consisting of hydrogen, alkyl, aryl and aralkyl; and

each R<sup>10</sup> is independently selected from the group consisting of a straight or branched alkylene and a straight or branched alkenylene chain,

as a single stereoisomer, a mixture of stereoisomers, or as a racemic mixture of stereoisomers;

or a pharmaceutically acceptable salt, solvate or prodrug thereof compound of Claim (I);



wherein:

the A, C or D ring is independently fully saturated, partially saturated or fully unsaturated;  
 C1, C4, C11, C12, C15 and C16 are each independently substituted with two of the  
 following, which are independently selected: hydrogen, alkyl,  $R^8-OR^7$ , or  $R^8-N(R^7)_2$ , provided  
 that C4 is not substituted by two methyl groups;

C9 and C14 are each independently substituted with hydrogen, alkyl,  $R^8-OR^7$ , or  
 $R^8-N(R^7)_2$ ;

$R^1$  is  $OR^7$  or  $N(R^7)_2$ ;

$R^2$  and  $R^3$  are each independently selected from the group consisting of  $R^8-OR^7$ ,  
 $R^8-OC(O)R^9$ ,  $R^{10}-N(R^7)_2$ ,  $R^{10}-N(R^9)C(O)R^9$ ,  $R^{10}-N(R^9)S(O)_tR^9$  (where t is 1 or 2),  
 $R^{10}-N(R^9)C(NR^9)N(R^9)_2$ , alkyl, alkenyl, optionally substituted aralkyl, optionally substituted  
 aralkenyl, optionally substituted heterocyclalkyl, optionally substituted heteroarylalkyl,  
 optionally substituted heteroarylalkenyl, and optionally substituted heteroarylalkenyl;

$R^{4a}$  and  $R^{4b}$  are each independently selected from hydrogen, alkenyl or alkynyl;

or  $R^{4a}$  is hydrogen, alkenyl or alkynyl and  $R^{4b}$  is a direct bond to the carbon at C16;

or  $R^{4a}$  and  $R^{4b}$  together form alkylidene or haloalkylidene;

$R^5$  is alkyl or  $R^5$  is a direct bond to the carbon at C14;

$R^6$  is hydrogen,  $R^8-OR^7$  or  $R^8-N(R^7)_2$ ;

each  $R^7$  is independently selected from the group consisting of hydrogen,  $R^{10}-OR^9$ ,  
 $R^{10}-N(R^9)_2$ , alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl,  
 optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclalkyl,  
 optionally substituted heteroaryl and optionally substituted heteroarylalkyl;


each  $R^8$  is independently selected from the group consisting of a direct bond, a straight  
 or branched alkylene chain, and a straight or branched alkenylene chain;

each  $R^9$  is independently selected from the group consisting of hydrogen, alkyl, aryl and  
 aralkyl; and

~~each  $R^{10}$  is independently selected from the group consisting of a straight or branched alkylene and a straight or branched alkenylene chain;~~  
~~as a single stereoisomer, a mixture of stereoisomers, or as a racemic mixture of stereoisomers;~~  
~~or a pharmaceutically acceptable salt, solvate or prodrug thereof.~~

23. (Cancelled)

24. (Withdrawn and Currently Amended) A method of treating an inflammatory condition or disease in a mammal, which method comprises administering to the mammal in need thereof a therapeutically effective amount of a compound having the following formula (Ia):



wherein:

the A, C or D ring is independently fully saturated;

C1, C4, C11, C12, C15 and C16 are each independently substituted with two hydrogens;

C9 and C14 are each independently substituted with hydrogen;

$R^1$  is  $-OR^7$ ;

$R^2$  is  $-R^8-OR^7$ ;

$R^3$  is  $-R^{10}-N(R^7)_2$ ;

$R^{4a}$  and  $R^{4b}$  together form alkylidene or haloalkylidene;

$R^5$  is alkyl;

$R^6$  is hydrogen,  $-R^8-OR^7$  or  $-R^8-N(R^7)_2$ ;

each  $R^7$  is independently selected from the group consisting of hydrogen,  $-R^{10}-OR^9$ ,  $-R^{10}-N(R^9)_2$ , alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl;


each  $R^8$  is independently selected from the group consisting of a direct bond, a straight or branched alkylene chain, and a straight or branched alkenylene chain;

each  $R^9$  is independently selected from the group consisting of hydrogen, alkyl, aryl and aralkyl; and

each  $R^{10}$  is independently selected from the group consisting of a straight or branched alkylene and a straight or branched alkenylene chain,

as a single stereoisomer, a mixture of stereoisomers, or as a racemic mixture of stereoisomers;

or a pharmaceutically acceptable salt, solvate or prodrug thereof compound of formula (I):



wherein:

the A, C or D ring is independently fully saturated, partially saturated or fully unsaturated;  
~~C1, C4, C11, C12, C15 and C16 are each independently substituted with two of the following, which are independently selected: hydrogen, alkyl,  $-R^8-OR^7$ , or  $-R^8-N(R^7)_2$ , provided that C4 is not substituted by two methyl groups;~~

~~C9 and C14 are each independently substituted with hydrogen, alkyl,  $-R^8-OR^7$ , or  $-R^8-N(R^7)_2$ ;~~

~~$R^1$  is  $-OR^7$  or  $-N(R^7)_2$ ;~~

~~$R^2$  and  $R^3$  are each independently selected from the group consisting of  $-R^8-OR^7$ ,  $-R^8-OC(O)R^9$ ,  $-R^{10}-N(R^7)_2$ ,  $-R^{10}-N(R^9)C(O)R^9$ ,  $-R^{10}-N(R^9)S(O)_tR^9$  (where t is 1 or 2),  $-R^{10}-N(R^9)C(NR^8)N(R^9)_2$ , alkyl, alkenyl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted heterocyclylalkyl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, and optionally substituted heteroarylalkenyl;~~

~~$R^{4a}$  and  $R^{4b}$  are each independently selected from hydrogen, alkenyl or alkynyl;~~

~~or  $R^{4a}$  is hydrogen, alkenyl or alkynyl and  $R^{4b}$  is a direct bond to the carbon at C16;~~

~~or  $R^{4a}$  and  $R^{4b}$  together form alkylidene or haloalkylidene;~~

~~$R^5$  is alkyl or  $R^5$  is a direct bond to the carbon at C14;~~

~~R<sup>6</sup> is hydrogen, -R<sup>8</sup>-OR<sup>7</sup> or -R<sup>8</sup>-N(R<sup>7</sup>)<sub>2</sub>;~~

~~each R<sup>7</sup> is independently selected from the group consisting of hydrogen, -R<sup>10</sup>-OR<sup>9</sup>, -R<sup>10</sup>-N(R<sup>9</sup>)<sub>2</sub>, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl;~~

~~each R<sup>8</sup> is independently selected from the group consisting of a direct bond, a straight or branched alkylene chain, and a straight or branched alkenylene chain;~~

~~each R<sup>9</sup> is independently selected from the group consisting of hydrogen, alkyl, aryl and aralkyl; and~~

~~each R<sup>10</sup> is independently selected from the group consisting of a straight or branched alkylene and a straight or branched alkenylene chain;~~

~~as a single stereoisomer, a mixture of stereoisomers, or as a racemic mixture of stereoisomers;~~

~~or a pharmaceutically acceptable salt, solvate or prodrug thereof.~~

25. (Cancelled)

26. (Withdrawn and Currently Amended) The method of Claim 24 ~~or Claim 25~~ wherein the inflammatory condition or disease is selected from the group consisting of the following:

arthritis (including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, osteoarthritis, gout, and synovitis), inflammations of the brain (including multiple sclerosis, Alzheimer's, AIDS dementia, stroke, encephalitis, trauma, and Creutzfeld-Jakob disease), inflammatory bowel disease (including Crohn's disease and ulcerative colitis), irritable bowel syndrome, ischemia-reperfusion injury (including myocardial infarction), sarcoidosis, psoriasis, tissue/organ transplant, graft vs host disease, systemic lupus erythematosus, Type I juvenile diabetes, vasculitis, atherosclerosis, cardiomyopathy, autoimmune myocarditis, atopic dermatitis, asthma, allergy, allergic rhinitis, and chronic obstructive pulmonary disease (including emphysema and bronchitis).

27.-29. (Cancelled)